Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has released its financial results for the second quarter of fiscal year 2027 (Q2 FY27). The company reported a significant 39.9% year-on-year increase in total revenue, reaching ₹13,630 million. EBITDA also saw a substantial growth of 34.0% to ₹2,789 million, demonstrating robust operational performance and expansion.
KIMS Hospitals Announces Strong Q2 FY27 Financial Performance
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has announced its financial and operational highlights for the second quarter ended September 30, 2026. The company has demonstrated strong growth across key financial metrics, reflecting its sustained operational excellence and strategic expansion initiatives.
Financial Highlights
In the second quarter of fiscal year 2027 (Q2 FY27), KIMS Hospitals reported a total revenue of ₹13,630 million, marking a substantial year-on-year (YoY) increase of 39.9% from ₹9,649 million in Q2 FY26. EBITDA also saw a significant rise of 34.0% YoY, reaching ₹2,789 million compared to ₹2,082 million in the same period last year. The EBITDA margin stood at 20.5%.
For the first half of fiscal year 2027 (H1 FY27), total revenue grew by 38.8% YoY to ₹25,589 million. EBITDA for H1 FY27 was ₹5,187 million, an increase of 27.2% YoY. The EBITDA margin for H1 FY27 was 20.3%.
Profit After Tax (PAT) for Q2 FY27 stood at ₹757 million, showing a 5.1% YoY increase. Diluted Earnings Per Share (EPS) for Q2 FY27 was ₹1.81.
Operational Highlights
Operational performance also saw positive trends. IP Volume in Q2 FY27 increased by 27.0% YoY to 81,668. OP Volume saw a growth of 23.3% YoY, reaching 7,31,010. ARPOB (Average Revenue Per Operating Bed) increased by 14.9% YoY to ₹48,277, and ARPP (Average Revenue Per Patient) grew by 9.9% YoY to ₹1,65,577.
The company’s occupancy rate for Q2 FY27 was 54.3%.
These results reflect the company’s continued expansion and its ability to drive both revenue and profitability in the competitive healthcare landscape.
Source: BSE
